Oct 1, 2000 | NEWS
Genzyme Corporation and it’s development partner, Pharming N.V., are committed to providing an effective and practical therapy for Pompe disease that can be made available to the greatest number of patients in the shortest possible time. As part of this commitment,...
Jul 30, 2000 | NEWS
The Lancet—July 29, 2000 Recombinant human alpha-glucosidase from rabbit milk in Pompe patients Lancet 2000; 356: 397-398 Hannerieke Van den Hout, Arnold J J Reuser, Arnold G Vulto, M Christa B Loonen, Adri Cromme-Dijkhuis, Ans T Van der Ploeg Following is a short...
Apr 20, 2000 | NEWS
Genzyme and Pharming to Fund Commercialization Cambridge, Mass., USA, Durham, N.C., USA, and Leiden, the Netherlands, April 19, 2000 – Genzyme General and Synpac (North Carolina) today announced an agreement under which Genzyme will obtain exclusive, worldwide...
Mar 15, 2000 | NEWS
Pharming’s first Phase II clinical trial for Pompe’s disease finalised, showing survival, skeletal muscle regeneration and overall improvement of heart and lung functions Leiden, the Netherlands, March 15, 2000 The bio-pharmaceutical company Pharming Group N.V....
Dec 5, 1999 | NEWS
New York University Medical Center Frank Martiniuk, Ph.D. A collaborative effort to test animal models with enzyme and gene replacement is underway. Dr. Martiniuk is sending the human gene and acid a-glucosidase to Australia to be tested in March on cattle affected by...
Aug 4, 1999 | NEWS
Applied Biological Sciences Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid alpha glucosidase…………. National Academy of Sciences Vol. 96, Issue 16,...
Aug 3, 1999 | NEWS
News Release by Karyn Hede Duke Medical Center News Office August 2, 1999 Using a modified virus to deliver a therapeutic gene, scientists at Duke University Medical Center have shown that, in mice, they can reverse the damage caused by an inherited muscle-wasting...
Jul 4, 1999 | NEWS
The first IPA Conference was held on July 2-4, 1999, in Naarden, the Netherlands. The meeting was attended by over 60 participants from 11 countries which included members of the medical and scientific community, patient organizations and industry. Presentations...
Jun 30, 1999 | NEWS
The following status statement was released by Synpac (North Carolina), Inc., on June 30, 1999 The following status statement was released by Synpac (North Carolina), Inc., on June 30, 1999 Synpac Pharmaceuticals Limited Cambois, Bedlington, Northumberland NE22 7DB...
Jun 26, 1999 | NEWS
The following article by Laura Spinney appears in BioMednews Reports (6- 25-99,#57) Glycogen storage disease type II causes enlargement of certain muscles, particularly the heart and tongue, due to their inability to break down glycogen. A team of American scientists...
